YOLFTbeta
Larimar Therapeutics Inc

Larimar Therapeutics Inc

LRMR · NASDAQ · Healthcare / Biotechnology

3.02USD+0.32 (+11.85%)

Price History

Full chart

Market Stats

Previous Close2.70
Open3.01
Day Range2.84 – 3.08
52-Week Range2.72 – 6.42
Volume2.53M
Market Cap319.44M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.72
Dividend Yield0.00%
Beta0.75
50-Day Avg3.97
200-Day Avg3.95

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Carole S. Ben-Maimon M.D.
  • Employees71
  • HeadquartersThree Bala Plaza East, Bala Cynwyd, PA, United States, 19004, USA
  • Websitehttps://www.larimartx.com

Leadership

  • Dr. Carole S. Ben-Maimon M.D.CEO, President & Director · b. 1959
  • Mr. Michael Celano CPASecretary & CFO · b. 1959
  • Dr. Gopi Shankar M.B.A., Ph.D.Chief Development Officer · b. 1971
  • Mr. John BermanVice President of Finance & Administration
  • Ms. Jennifer Spokes JohanssonVice President of Legal & Compliance
  • Dr. Russell G. Clayton Sr., D.O.Chief Medical Officer · b. 1961
  • Mr. Francis Michael Conway CPAVP & Controller

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--------0000000
Cost of Revenue4.00K11.00K12.00K-70.00K212.00K188.00K261.00K78.00K155.00K326.00K272.00K311.00K318.00K350.00K
Gross Profit-4.00K-11.00K-12.00K--70.00K-212.00K-188.00K-261.00K-78.00K-155.00K-326.00K-272.00K-311.00K-318.00K-350.00K
Operating Expense13.15M13.78M13.77M-73.74M56.91M53.69M62.46M23.14M42.65M50.14M36.25M41.45M90.57M172.15M
Operating Income-13.15M-13.79M-13.78M-35.53M-73.81M-57.12M-53.88M-62.72M-23.21M-42.80M-50.47M-36.53M-41.76M-90.89M-172.50M
EBITDA-13.15M-13.77M-14.02M-35.53M-73.41M-57.44M-52.58M-60.81M-23.14M-42.65M-50.14M-36.21M-36.64M-80.29M-165.32M
Net Income-13.16M-13.88M-14.03M-36.57M-74.29M-57.88M-52.03M-61.37M-23.13M-42.33M-50.31M-34.18M-36.95M-80.60M-165.67M
R&D11.40M11.54M9.56M27.39M54.62M39.77M41.74M49.53M20.79M31.41M38.40M24.25M27.67M73.28M154.22M
Interest Expense-97.00K-870.00K806.00K347.00K971.00K246.00K1.77M0326.00K318.00K---

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-10.99M38.14M117.52M189.11M131.62M105.51M121.76M5.20M104.69M78.67M126.41M95.94M200.22M145.84M
Total Liabilities-2.93M2.92M13.08M20.00M9.89M27.29M28.49M5.89M14.99M14.25M15.50M14.21M28.41M67.76M
Total Equity-8.06M35.22M104.44M169.11M121.73M78.22M93.27M-694.00K89.69M64.41M110.90M81.72M171.81M78.08M
Cash-9.94M35.52M58.10M35.59M32.35M40.78M49.33M1.01M68.15M70.10M26.82M26.75M33.22M85.41M
Total Debt---7.56M6.39M3.59M20.00M20.64M8.56M6.52M6.00M5.41M5.55M5.12M4.07M
Net Debt--9.94M-35.52M-50.55M-29.21M-28.76M-20.78M-28.69M-912.00K-61.63M-64.09M-21.42M-21.20M-28.10M-81.34M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.27M-13.59M-15.00M-28.24M-59.55M-51.98M-43.78M-51.49M-22.70M-42.20M-42.10M-27.57M-33.46M-70.76M-113.20M
Investing Cash Flow-45.00K-2.00K-17.00K-57.31M-92.12M51.45M35.65M-6.87M-83.00K17.09M24.17M-90.96M33.35M-85.39M100.31M
Financing Cash Flow10.07M22.06M40.60M108.14M129.16M-2.71M16.56M66.91M19.39M93.59M19.89M75.26M30.00K161.88M65.09M
Capital Expenditure35.00K2.00K17.00K58.00K595.00K660.00K55.00K108.00K83.00K62.00K333.00K100.00K164.00K515.00K91.00K
Free Cash Flow-12.31M-13.59M-15.02M-28.30M-60.15M-52.63M-43.84M-51.59M-22.78M-42.26M-42.44M-27.67M-33.62M-71.28M-113.29M
FCF to OCF100.29%100.01%100.11%100.21%101.00%101.27%100.13%100.21%100.37%100.15%100.79%100.36%100.49%100.73%100.08%

Earnings

Report DateAug 13, 2014Nov 11, 2014Mar 19, 2015May 12, 2015Aug 11, 2015Nov 10, 2015Mar 9, 2016May 10, 2016Aug 4, 2016Nov 9, 2016Mar 9, 2017May 9, 2017Aug 8, 2017Nov 7, 2017Mar 6, 2018May 8, 2018Aug 7, 2018Nov 7, 2018Mar 11, 2019May 9, 2019Aug 8, 2019Nov 6, 2019Mar 5, 2020May 8, 2020Aug 11, 2020Nov 10, 2020Mar 4, 2021May 10, 2021Aug 12, 2021Nov 12, 2021Mar 25, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 14, 2023May 15, 2023Aug 10, 2023Nov 14, 2023Mar 14, 2024May 9, 2024Aug 7, 2024Oct 30, 2024Mar 12, 2025Apr 30, 2025Aug 14, 2025Nov 5, 2025Mar 18, 2026May 14, 2026Aug 4, 2026Nov 4, 2026
EPS Estimate-30.93-11.07-7.85-7.74-8.49-9.50-9.58-8.85-7.94-7.28-6.03-5.21-6.24-6.92-6.84-6.18-7.08-5.64-5.26-5.09-4.38-3.20-2.28-2.28-2.16-2.28-0.70-0.86-0.75-0.66-0.72-0.51-0.57-0.42-0.37-0.25-0.21-0.23-0.25-0.24-0.32-0.37-0.32-0.41-0.49-0.39-0.49-0.59-0.39-0.39
EPS Actual-33.12-7.20-5.76-6.36-7.92-8.76-10.20-7.80-6.60-6.48-4.56-5.76-5.88-5.52-5.76-6.96-6.84-4.92-4.68-4.20-3.84-2.88-2.28-1.20-1.21-0.64-0.89-0.76-0.79-0.92-0.50-0.49-0.47-0.37-0.21-0.15-0.19-0.21-0.30-0.27-0.34-0.24-0.45-0.46-0.41-0.61-0.73-0.31-0.30-
Surprise-7.08%34.96%26.62%17.83%6.71%7.79%-6.47%11.86%16.88%10.99%24.38%-10.56%5.77%20.23%15.79%-12.62%3.39%12.77%11.03%17.49%12.33%10.00%0.00%47.37%43.98%71.93%-27.14%11.63%-5.33%-39.39%30.56%3.92%17.54%11.90%43.24%40.00%9.52%8.70%-20.00%-12.50%-6.25%35.14%-40.89%-12.20%16.33%-56.41%-48.98%47.46%23.08%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap319.44M
Enterprise Value250.20M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.15
EPS-1.72
Book Value1.22
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-178.68M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-139.63%
Return on Assets-70.96%
Shares Outstanding103.88M
Shares Float57.90M
Beta0.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 14.40
  • Strong Buy
    10
  • Buy
    1

Ownership Breakdown

Institutions
93.42%
Insiders
1.15%
Retail / Other
5.43%

Top Institutional Holders

  • Deerfield Management Co
    35.61M34.28%
  • Blue Owl Capital Holdings LP
    9.16M8.82%
  • BlackRock Inc
    3.75M3.61%
  • Defilade Capital Management, L.P.
    3.67M3.53%
  • Driehaus Capital Management LLC
    2.93M2.82%
  • Vanguard Capital Management, LLC
    2.87M2.76%
  • Dafna Capital Management LLC
    2.01M1.93%
  • The Goldman Sachs Group Inc
    1.56M1.50%
  • RTW INVESTMENTS, LLC
    1.50M1.44%
  • Citadel Advisors Llc
    1.46M1.40%
  • Woodline Partners LP
    1.40M1.35%
  • Millennium Management LLC
    1.33M1.28%
  • Geode Capital Management, LLC
    1.11M1.07%
  • Point72 Asset Management, L.P.
    1.05M1.01%
  • Dimensional Fund Advisors, Inc.
    961.08K0.93%
  • Marshall Wace Asset Management Ltd
    933.46K0.90%
  • State Street Corp
    911.33K0.88%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.21M2.12%
  • iShares Russell 2000 ETF
    1.70M1.64%
  • Fidelity Enhanced Small Cap Core ETF
    937.22K0.90%

Stock Splits

  • May 29, 20201:12